TAGRISSO Osimertinib 40mg & 80mg Tablet

Tagrisso (Osimertinib) is used for the 1st-line treatment of patients with metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).

Manufacturer :  AstraZeneca

Strengths available :   40mg & 80mg tablets

Storage : Store at temperature between 20°C – 25°C

It  is US FDA approved medicine

Dosage :

Recommended Dosage :

The recommended dose of TAGRISSO is 80 mg tablet once a day until disease progression or unacceptable toxicity. TAGRISSO can be taken with or without food.

Dosage for Patients who Difficulty Swallowing Solids :

Disperse tablet in 60 mL (2 ounces) of non-carbonated water only. Stir until tablet is dispersed into small pieces (the tablet will not completely dissolve) and swallow immediately. Do not crush, heat, or ultrasonicate during preparation. Rinse the container with 120 mL to 240 mL (4 to 8 ounces of) water and immediately drink.

If administration via nasogastric tube is required, disperse the tablet as above in 15 mL of non-carbonated water, and then use an additional 15 mL of water to transfer any residues to the syringe. The resulting 30 mL liquid should be administered as per the nasogastric tube instructions with appropriate water flushes (approximately 30 mL).

Most common side effects are Diarrhoea, Stomatitis (Inflammation of the mouth), Rash, Loss of appetite.

30 x 1 tablets